PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.15%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
3110.63%
G&A change of 3110.63% while TRVN maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11227.11%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
11227.11%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
26362.71%
Interest expense growth while TRVN reduces costs. John Neff would investigate differences.
-84.19%
D&A reduction while TRVN shows 6.74% growth. Joel Greenblatt would examine efficiency.
-40.83%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-9873.13%
Operating income decline while TRVN shows 14.24% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-850.18%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-16129.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
155593.20%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
-16129.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-12933.18%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-12933.18%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
24.22%
Share count reduction below 50% of TRVN's 0.01%. Michael Burry would check for concerns.
24.22%
Diluted share reduction below 50% of TRVN's 0.01%. Michael Burry would check for concerns.